Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Avid Bioservices, Inc.
Avid Bioservices, Inc. News
Jun 16, 2025 - businesswire.com
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
Jun 12, 2025 - prnewswire.com
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
Avid Bioservices, Inc. Quantitative Score
About Avid Bioservices, Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Avid Bioservices, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Avid Bioservices, Inc. Financials
Table Compare
Compare CDMO metrics with: | |||
|---|---|---|---|
Earnings & Growth | CDMO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CDMO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CDMO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CDMO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Avid Bioservices, Inc. Income
Avid Bioservices, Inc. Balance Sheet
Avid Bioservices, Inc. Cash Flow
Avid Bioservices, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Avid Bioservices, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.6600 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2018-04-02 | 0.66 | Quarterly |
Historical Market Cap
Shares Outstanding
Avid Bioservices, Inc. Executives
| Name | Role |
|---|---|
| Mr. Nicholas Stewart Green B.Sc., MBA | President, Chief Executive Officer & Director |
| Mr. Daniel R. Hart | Chief Financial Officer |
| Mr. Mark R. Ziebell J.D. | Vice President, General Counsel & Corporate Secretary |
| Mr. Richard A. Richieri | Chief Operations Officer |
| Mr. Matthew R. Kwietniak | Chief Commercial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Nicholas Stewart Green B.Sc., MBA | President, Chief Executive Officer & Director | Male | 1965 | 699.01K |
| Mr. Daniel R. Hart | Chief Financial Officer | Male | 1973 | 497.16K |
| Mr. Mark R. Ziebell J.D. | Vice President, General Counsel & Corporate Secretary | Male | 1964 | 477.16K |
| Mr. Richard A. Richieri | Chief Operations Officer | Male | 1965 | 411.91K |
| Mr. Matthew R. Kwietniak | Chief Commercial Officer | Male | 1969 | 409.43K |
Avid Bioservices, Inc. Insider Trades
| Date | 5 Feb |
| Name | Ziebell Mark R |
| Role | V. P., General Counsel |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 66799 |
| Date | 5 Feb |
| Name | Ziebell Mark R |
| Role | V. P., General Counsel |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 14286 |
| Date | 5 Feb |
| Name | Ziebell Mark R |
| Role | V. P., General Counsel |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 21429 |
| Date | 5 Feb |
| Name | Ziebell Mark R |
| Role | V. P., General Counsel |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 98120 |
| Date | 5 Feb |
| Name | Ziebell Mark R |
| Role | V. P., General Counsel |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 55310 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 5 Feb | Ziebell Mark R | V. P., General Counsel | Disposed | D-Return | 66799 |
| 5 Feb | Ziebell Mark R | V. P., General Counsel | Disposed | D-Return | 14286 |
| 5 Feb | Ziebell Mark R | V. P., General Counsel | Disposed | D-Return | 21429 |
| 5 Feb | Ziebell Mark R | V. P., General Counsel | Disposed | D-Return | 98120 |
| 5 Feb | Ziebell Mark R | V. P., General Counsel | Disposed | D-Return | 55310 |